1. Search Result
Search Result
Results for "

neurological disorder

" in MedChemExpress (MCE) Product Catalog:

150

Inhibitors & Agonists

5

Screening Libraries

3

Biochemical Assay Reagents

1

Peptides

16

Natural
Products

6

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W275048

    Monoamine Oxidase Neurological Disease
    MAO-A inhibitor 3 (Compound 360) is a MAO-A inhibitor, with IC50 of >100 μΜ. MAO-A inhibitor 3 can be used to study neurological disorders .
    MAO-A inhibitor 3
  • HY-169929

    NKCC Neurological Disease
    KCC2 potentiators-1 (Compound 2) is a Potassium chloride cotransporter-2 (KCC2) potentiator. KCC2 potentiators-1 is promising for research of neurological disorder .
    KCC2 potentiators-1
  • HY-147132

    iGluR Neurological Disease
    GluR6 antagonist-1 is a benzothiophene derivative, acting as a GluR6 antagonist. GluR6 antagonist-1 can be used for researching acute and chronic neurological disorders .
    GluR6  antagonist-1
  • HY-15442

    BINA

    mGluR Neurological Disease
    Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders .
    Biphenylindanone A
  • HY-12495A
    ISRIB
    10+ Cited Publications

    Biochemical Assay Reagents Eukaryotic Initiation Factor (eIF) Neurological Disease
    ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research .
    ISRIB
  • HY-129030

    iGluR Neurological Disease
    BDZ-g is a potent, selective antagonist of AMPA receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .
    BDZ-g
  • HY-145945

    MAGL Neurological Disease
    MAGL-IN-6 is a potent MAGL inhibitor with an IC50 of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234) .
    MAGL-IN-6
  • HY-151800

    Monoamine Oxidase Neurological Disease
    MAO-A/B-IN-2 (compound 30) is a MAO-A/B inhibitor with IC50 values of 17.8 and 15.8 μM for MAO-A and MAO-B, respectively. MAO-A/B-IN-2 can be used in the study of neurological disorders .
    MAO-A/B-IN-2
  • HY-171790

    NSC 294839

    5-HT Receptor Neurological Disease
    W-2451 (NSC 294839) is a selective serotonin 5-HT2 receptor antagonist. W-2451 is promising for research of neurological disorders .
    W-2451
  • HY-120811

    iGluR Neurological Disease
    PF-04701475 is a potent AMPA receptor potentiator with an EC50 of 123 nM. PF-04701475 can be used for the study of neurological disorders .
    PF-04701475
  • HY-14225

    CRFR Cytochrome P450 Neurological Disease
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer .
    BMS-764459
  • HY-136660

    mTOR Neurological Disease
    PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .
    PQR626
  • HY-139307

    Tau Protein Neurological Disease
    MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research .
    MG-2119
  • HY-160548

    mTOR Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders .
    mTOR inhibitor-18
  • HY-146101

    iGluR Neurological Disease
    NMDA receptor antagonist 5 (Compound 10e) is a potent, brain permeable and non-toxic NMDA receptor antagonist. NMDA receptor antagonist 5 can be used for neurological disorder research .
    NMDA receptor antagonist 5
  • HY-W726667A

    (R)-Citramalate lithium; (2R)-Methylmalic acid lithium

    Drug Isomer Neurological Disease Metabolic Disease
    (R)-(-)-Citramalic acid ((R)-Citramalate) lithium, a lithium salt of Citramalic acid, is the R enantiomer of Citramalic acid lithium. (R)-(-)-Citramalic acid lithium is involved in the metabolism of glutamate through the methylaspartate pathway. (R)-(-)-Citramalic acid lithium is promising for research of neurological disorders .
    (R)-(-)-Citramalic acid lithium
  • HY-124576

    MAGL Neurological Disease
    ABD-1970 is a selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 15 nM and 29 nM for human and mouse MAGL, respectively. ABD-1970 shows selectivity for MGLL over other members of the serine hydrolase class. ABD-1970 has the potential for the study of neurological disorders .
    ABD-1970
  • HY-146076

    5-HT Receptor Neurological Disease
    5-HT6/5-HT2A receptor ligand-1 (compound 33) is a dual 5-HT6/5-HT2A receptor antagonist, with a Ki of 2 nM and 11 nM, respectively. 5-HT6/5-HT2A receptor ligand-1 has the potential for neurological and psychiatric disorders research .
    5-HT6/5-HT2A receptor ligand-1
  • HY-103568

    mGluR Neurological Disease
    YM-298198 hydrochloride is a high-affinity, selective, orally active, and non-competitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders .
    YM-298198 hydrochloride
  • HY-132811

    CORT113176

    Glucocorticoid Receptor Neurological Disease Inflammation/Immunology
    Dazucorilant (CORT113176) is a selective and high affinity non-steroidal glucocorticoid receptor (GR) modulator with a Ki value <1 nM in vitro. Dazucorilant can be used for the research of neurological disorders .
    Dazucorilant
  • HY-143391

    iGluR Neurological Disease
    NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator. NMDA receptor modulator 3 can be used for neurological disorder research .
    NMDA receptor modulator 3
  • HY-143390

    iGluR Neurological Disease
    NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator. NMDA receptor modulator 2 can be used for neurological disorder research .
    NMDA receptor modulator 2
  • HY-143396

    iGluR Neurological Disease
    NMDA receptor modulator 5 (Compound 195) is a potent NMDA receptor modulator. NMDA receptor modulator 5 can be used for neurological disorder research .
    NMDA receptor modulator 5
  • HY-143393

    iGluR Neurological Disease
    NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator. NMDA receptor modulator 4 can be used for neurological disorder research .
    NMDA receptor modulator 4
  • HY-143397

    iGluR Neurological Disease
    NMDA receptor modulator 6 (Compound 183) is a potent NMDA receptor modulator. NMDA receptor modulator 6 can be used for neurological disorder research .
    NMDA receptor modulator 6
  • HY-105182
    Xanomeline
    2 Publications Verification

    LY-246708

    mAChR Neurological Disease
    Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia .
    Xanomeline
  • HY-160168

    Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-139059

    Others Neurological Disease
    ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research .
    ERD03
  • HY-157041

    MAGL Cancer
    MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .
    MAGL-IN-10
  • HY-108683

    Orexin Receptor (OX Receptor) Neurological Disease
    ACT-335827 is a selective, orally active, brain-penetrant orexin type 1 receptor antagonist. ACT-33582 acts on OXR1 and OXR2 with IC50 values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders .
    ACT-335827
  • HY-152183

    DYRK Neurological Disease
    FINDY is a folding intermediate-selective inhibitor of DYRK1A. FINDY can inhibit Ser97 autophosphorylation with an IC50 value of 35 μM. FINDY can be used for the research of neurological disorder . FINDY is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FINDY
  • HY-105182R

    LY-246708 (Standard)

    mAChR Neurological Disease
    Xanomeline (Standard) is the analytical standard of Xanomeline. This product is intended for research and analytical applications. Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia .
    Xanomeline (Standard)
  • HY-122697

    Potassium Channel Cardiovascular Disease Neurological Disease Endocrinology
    ML418 is a potent, selective and CNS penetrating Kir7.1 potassium channel blocker. ML418 inhibits Kir7.1 with an IC50 value of 0.31 μM. ML418 can be used for the research of neurological, cardiovascular, endocrine and muscle disorders.
    ML418
  • HY-103462

    FAAH Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-12152
    PNU-120596
    1 Publications Verification

    NSC 216666

    nAChR Neurological Disease Inflammation/Immunology
    PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .
    PNU-120596
  • HY-116418

    Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .
    Virodhamine
  • HY-106017

    Potassium Channel Sodium Channel Neurological Disease
    Nerispirdine is an ion channel inhibitor with IC50s of 3.6, 3.7 and 11.9 μM against K(v)1.1, K(v)1.2 and voltage-dependent Na(+) channel, respectively. Nerispirdine is a 4-aminopyridine (4-AP, HY-B0604) derivative and can be utilized in research on neurological disorders .
    Nerispirdine
  • HY-110194

    Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .
    Virodhamine TFA
  • HY-40294

    Monoamine Oxidase GSK-3 LRRK2 Cardiovascular Disease Neurological Disease Cancer
    Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .
    Indazole
  • HY-151094

    Monoamine Oxidase Neurological Disease
    FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .
    FTEAA
  • HY-118814

    iGluR Neurological Disease
    YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. YM928 inhibits AMPA receptor-mediated toxicity in primary rat hippocampal cultures with an IC50 value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC50 value of 3 μM and antagonizes AMPA-induced inward currents with an IC50 value of 1 μM. YM928 is promising for research of neurological disorders .
    YM928
  • HY-168060

    PKC Neurological Disease
    (8R)-8-Hydroxyepoxyboetirane A is a neurogenic compound that interacts with PKC δ-C1B. (8R)-8-Hydroxyepoxyboetirane A binds to the PKC enzyme pocket via hydrogen bonds with Gly-253, Leu-251 and Thr242. (8R)-8-Hydroxyepoxyboetirane A induces NRG1 release and differentiation of NSC into neurons. (8R)-8-Hydroxyepoxyboetirane A is promising for research of neurological disorders .
    (8R)-8-Hydroxyepoxyboetirane A
  • HY-117656
    ESI-05
    3 Publications Verification

    NSC 116966

    Acyltransferase Neurological Disease Metabolic Disease
    ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC50 of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .
    ESI-05
  • HY-19999A
    PF-CBP1 hydrochloride
    1 Publications Verification

    Epigenetic Reader Domain Histone Acetyltransferase Neurological Disease
    PF-CBP1 hydrochloride is a highly selective inhibitor of the CREB binding protein bromodomain (CBP BRD). PF-CBP1 inhibits CREBBP and EP300 bromodomains with?IC50?of 125 nM and 363 nM respectively. PF-CBP1 hydrochloride reduces LPS-induced inflammatory cytokines expression (IL-1β,?IL-6?and?IFN-β) in primary macrophages. PF-CBP1 hydrochloride also downregulates?RGS4?expression cortical neurons and can be used for the research of neurological disorders, including epilepsy and parkinson's disease, et al .
    PF-CBP1 hydrochloride
  • HY-123264

    Potassium Channel Neurological Disease
    RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC50 of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .
    RL648_81
  • HY-111828
    TTA-A2
    1 Publications Verification

    Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
    TTA-A2
  • HY-172182

    VU6011887

    Potassium Channel Neurological Disease
    ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC50 values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.
    ONO-2920632
  • HY-172418

    mAChR Neurological Disease
    Betovumeline is the agonist for muscarinic receptor and can be used for researchs of neurological disorders .
    Betovumeline
  • HY-120564

    CRFR Neurological Disease
    BMS-763534 is a CRF1 antagonist that inhibits neurological disorders such as depression and anxiety. .
    BMS-763534
  • HY-148331

    Prolyl Endopeptidase (PREP) Neurological Disease
    Z-Thioprolyl-Thioproline is a bovine brain prolyl endopeptidase (PEP) inhibitor (IC50=16 µM; Ki=37 µM). Z-Thioprolyl-Thioproline is used in the study of neurological disorders such as memory disorders and cognitive disorders .
    Z-Thioprolyl-Thioproline

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: